Gonadotropin hormone (menotropin)
HMG
HMG (menotropins) is a gonadotropin preparation with FSH and LH activity extracted from the urine of postmenopausal women; the app lists a 36 hour half-life, the Menopur label 11 to 13 hours for FSH in its multiple-dose phase in healthy pre-menopausal women.1
HMG after one dose: 50% at ~36 h, 25% at 72 h, 12.5% at 108 h.
Drawn from the half-life in the app's model, ~36 h. The model's figures
- Compound
- HMG
- Symbol
- HMG
- Family
- Post-cycle and ancillaries
- Parts
- 14
- References
- 15
- Checked
- Last reviewed . Sources are listed below.
Overview
The Menopur label (Ferring) describes menotropins as "a preparation of gonadotropins (FSH and LH activity), extracted from the urine of postmenopausal women, which has undergone additional steps for purification".1 Each vial holds "75 International Units of follicle-stimulating hormone (FSH) activity and 75 International Units of luteinizing hormone (LH) activity", and the label adds that "Human Chorionic Gonadotropin (hCG) is detected in MENOPUR".1
The label's indication is "Development of multiple follicles and pregnancy in ovulatory women as part of an Assisted Reproductive Technology (ART) cycle", and its contraindications and trials are described in women.1 The app files HMG under post-cycle therapy; the label's indication does not mention that.1
In men, the studies below give hMG together with hCG: in congenital hypogonadotropic hypogonadism (CHH), in one case report of anabolic steroid-induced azoospermia and in idiopathic oligozoospermia.2,3,4 The app grades the evidence for HMG as moderate; that grade is the app's own.
How it works
Sources in this part
Per the Menopur label, menotropins given for 7 to 20 days "produces ovarian follicular growth and maturation in women who do not have primary ovarian failure", and "When sufficient follicular maturation has occurred, hCG must be given to induce ovulation".1
In men, the introduction of Liu and colleagues (Chinese Medical Journal, 2021) states, about recombinant FSH, that "exogenous FSH can stimulate Sertoli cells and spermatogonia, increase levels of anti-Müllerian hormone (AMH), and elevate testicular volume (TV) and sperm density"; this is background and not a result for hMG.5
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~36 h
- Bioavailability
- 95%
- Typical dose
- 75–150 IU
- Route
- SubQ / IM
- Time to peak
- ~12 h
The app lists a half-life of about 36 hours for HMG. The Menopur label reports that "The elimination half-lives for FSH in the multiple-dose phase were similar (11-13 hours) for subcutaneously administered MENOPUR and intramuscularly administered MENOPUR", from a crossover study in 33 healthy pre-menopausal women who had undergone pituitary suppression.1
Duijkers and colleagues (Human Reproduction, 1995) injected 225 IU each of two hMG preparations, Humegon and Pergonal, intravenously in 9 healthy women during triptorelin-induced suppression, one week apart.6 The FSH half-life was 22.20 h for Humegon and 21.33 h for Pergonal, and the HCG half-life was 14.80 h and 12.11 h.6
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | About 36 hours | FSH 11 to 13 hours after repeated subcutaneous or intramuscular Menopur in healthy women (label); after one intravenous 225 IU dose in 9 women, FSH 22.20 and 21.33 hours and HCG 14.80 and 12.11 hours1,6 |
| Bioavailability | 95% | No percentage in the label, which states that "The subcutaneous route of administration trends toward greater bioavailability than the intramuscular route for single and multiple doses of MENOPUR"1 |
| Time to peak | About 12 hours | FSH Tmax, mean (SD), in women: after one 225 IU dose 17.9 (5.8) hours subcutaneous and 27.5 (25.4) hours intramuscular; after repeated dosing 8.0 (3.0) and 9.0 (7.0) hours1 |
| Duration of activity | About 72 hours | No duration figure in the label or in the records cited1 |
| Route | Subcutaneous or intramuscular | The label is "for subcutaneous use"; its pharmacokinetic study and an ovulation induction trial also gave intramuscular injections1 |
Dobbs and colleagues (Fertility and Sterility, 1994) injected menotropin intramuscularly or subcutaneously in 7 women under leuprolide acetate suppression and report that "Peak serum FSH levels were higher and occurred earlier after IM injection than after SC injection".7 The label's single-dose Tmax runs the other way, later after intramuscular than after subcutaneous injection.1
The chart draws a one-compartment model with the app's half-life of 36 hours and time to peak of 12 hours, using schedules that the label or a study reports; with the label's FSH half-life of 11 to 13 hours the curve would fall faster.1,2,8
Human studies
The male studies below give hMG together with hCG, so a result belongs to the combination unless a row says otherwise; the trials in women compare menotropin with recombinant FSH.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Mao and colleagues, Asian Journal of Andrology, 20172 | Retrospective cohort: hCG/hMG against pulsatile GnRH, not randomised2 | 202 men with CHH: 182 on hCG/hMG, 20 on pulsatile GnRH2 | hCG 2000 U intramuscularly twice weekly for 3 months, then hMG 75 U added twice weekly (150 U if testes under 6 ml after 6 months of combined therapy); follow-up 28.7 ± 13.0 months2 | Sperm appeared in 140 of 182 men (76.9%) on hCG/hMG and 14 of 20 (70.0%) on GnRH (P = 0.580); median time to first sperm 18 months (95% CI 16.4 to 20.0) against 6 months (95% CI 1.6 to 10.4) with GnRH (P < 0.001)2 |
| Shah and colleagues, Pituitary, 20218 | Retrospective cohort, tertiary care centre8 | 35 men with CHH: 17 without and 18 with prior testosterone replacement8 | hMG 75 to 150 U three times a week plus escalating hCG; 33 ± 12 months8 | Spermatogenesis in 70%; median peak sperm count 9 million/ml without prior testosterone replacement against 0.05 million/ml with it (p = 0.004)8 |
| Ortaç and colleagues, Turkish Journal of Urology, 20209 | Retrospective comparison of hMG with recombinant FSH, each after hCG9 | 112 men with CHH (70 to receive hMG, 42 rFSH), mean age at diagnosis 27.9 years9 | Doses and length not given in the record9 | Sperm detected in 85.7% (96/112); successful spermatogenesis "similar (85.7%) in both groups"; pregnancy 38.6% (n=27) with hMG and 51.2% (n=21) with rFSH (p=0.314); "No patients developed severe effects"9 |
| Liu and colleagues, Chinese Medical Journal, 20215 | Retrospective cohort comparison of hCG/hMG (n = 20) with a GnRH pump (n = 21), 12 months5 | 41 male adolescents aged 12 to 18 with CHH5 | hCG 1000 to 2000 U for 3 months, then hMG with 75 U FSH and 75 U LH once daily5 | At 3 months testicular volume 5.1 ± 2.3 mL against 4.1 ± 1.8 mL (P > 0.05); penile length 6.9 ± 1.8 cm against 5.1 ± 1.6 cm (P < 0.05); at 6 months testosterone and the growth of penile length and diameter were greater with hCG/hMG and testicular volume did not differ significantly; at 9 to 12 months the testosterone level was higher with hCG/hMG and other parameters did not differ significantly5 |
| Zhao and colleagues, Andrologia, 20194 | Randomised, double-blinded, placebo-controlled4 | Men with idiopathic oligozoospermia; number not given in the record4 | hCG/hMG or placebo for 3 months; doses not given in the record4 | Sperm concentration, forward motility and morphology improved in the medium and higher inhibin B groups; "no significant differences in lower-level inhibin B group"4 |
| Menon, Fertility and Sterility, 20033 | Case report from a tertiary referral infertility centre3 | One man with azoospermia and male hypogonadotropic hypogonadism, a bodybuilder who reported using several anabolic steroids; azoospermia persisted after 1 year without them3 | hCG 10,000 IU twice weekly and hMG 75 IU daily, 3 months3 | Semen analyses returned to normal after 3 months; the couple conceived spontaneously 7 months later3 |
| Huijben and colleagues, Andrology, 202610 | Systematic review and meta-analysis of gonadotropin therapy10 | 50 studies, 1583 men with hypogonadotropic hypogonadism and azoospermia10 | Regimens varied, some with hMG (for example hCG 1500 IU/week with hMG 150 IU twice weekly)10 | Pooled spermatogenesis induction 74% (95% CI 66% to 82%) and pregnancy 52% (95% CI 42% to 62%) among couples with a child wish (24 studies, 463 men); the authors report that "most included studies were of poor methodological quality" and substantial heterogeneity in all intended meta-analyses, and the full text reports significant funnel plot asymmetry for spermatogenesis success (Egger p < 0.001), suggesting small-study effects or publication bias; no separate hMG result10 |
| European and Israeli Study Group, Fertility and Sterility, 200211 | Randomised, open label, parallel group phase III trial, 22 centres, women having IVF or ICSI11 | 781 women enrolled; 373 given HP-hMG and 354 recombinant FSH11 | Long GnRH agonist protocol; doses not given in the record11 | Ongoing pregnancy at 10 weeks, per protocol, 25% (85/344) with HP-hMG and 22% (71/317) with recombinant FSH; OHSS, miscarriage, adverse events and injection site reactions similar11 |
| Andersen and colleagues, Human Reproduction, 200612 | Randomised, assessor-blind, multinational trial, long GnRH agonist protocol12 | 731 women having IVF: 363 on HP-hMG, 368 on recombinant FSH12 | Stimulation doses not given in the record12 | Ongoing pregnancy per cycle 27% with HP-hMG and 22% with recombinant FSH (odds ratio 1.25, 95% CI 0.89 to 1.75); the authors state non-inferiority was established; fewer oocytes with HP-hMG (10.0 against 11.8, P < 0.001), top-quality embryos 11.3% with HP-hMG against 9.0% (P = 0.044), and lower estradiol (P = 0.031) and higher progesterone (P < 0.001) at the end of stimulation with recombinant FSH12 |
| Devroey and colleagues, Fertility and Sterility, 201213 | Randomised, open-label, assessor-blind, noninferiority trial (MEGASET), GnRH antagonist cycle, single blastocyst transfer13 | 749 women at 25 centres in 7 countries13 | Starting 150 IU daily for 5 days, maximum 375 IU daily, up to 20 days (registry)14 | Ongoing pregnancy after a fresh cycle 30% with hphMG and 27% with rFSH per protocol, 29% and 27% intention to treat; cumulative live birth for one stimulation cycle 40% and 38%13 |
Sources in this part
- 1Ferring Pharmaceuticals Inc, 2018
- 2Mao et al., 2017
- 3Menon, 2003
- 4Zhao et al., 2019
- 5Liu et al., 2021
- 8Shah et al., 2021
- 9Ortac et al., 2020
- 10Huijben et al., 2026
- 11European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone, 2002
- 12Andersen et al., 2006
- 13Devroey et al., 2012
- 14Ferring Pharmaceuticals, 2026
Deeper analysis: Mao and colleagues, Asian Journal of Andrology, 2017
Mao and colleagues (Peking Union Medical College Hospital, Beijing) analysed 202 Chinese men with CHH treated between January 2008 and December 2014 who had more than 12 months of follow-up.2 Testosterone therapy had been stopped for at least 3 months before either treatment began, and the hCG dose was adjusted to keep plasma testosterone at 10 to 15 nmol/l.2 Spermatogenesis induction was similar (76.9% against 70.0%, P = 0.580), and the authors conclude that "satisfactory results may be obtained more slowly with HCG/HMG treatment" and that "More prospective, randomized, and multicenter studies are needed".2
The authors list as limitations that the hCG/hMG group "had a longer follow-up time and a larger sample size", that the study was "retrospective" and "not randomized" with some patients choosing their group, and that GnRH dosing followed FSH and LH levels while hCG/hMG dosing followed testosterone, which "may compound differences seen in the spermatogenesis results".2 The PubMed record lists grant R37 HD019938 from the National Institute of Child Health and Human Development, and the authors state "All authors declare no competing interests".2
Deeper analysis: the Menopur label's IVF trial and a 2002 report
The label states that efficacy "was established in one randomized, open-label, multicenter, multinational (in Europe and Israel), comparative clinical trial" in women having IVF or ICSI after GnRH agonist pituitary suppression, with 373 women randomised to Menopur at a daily subcutaneous dose starting at 225 International Units.1 Continuing pregnancy was 87 of 373 (23%), described as "Non-inferior to comparator recombinant human FSH", and clinical pregnancy was 98 (26%), a secondary parameter for which the "Study was not powered to demonstrate differences".1 In the label's IVF trial OHSS occurred in 7.2% of the 373 women, and multiple pregnancy occurred in 35.3% (n=30) of 85 pregnancies.1
The label does not name the trial's authors or cite a report; the 2002 report by the European and Israeli Study Group gives 373 women treated with HP-hMG, in centres in six countries, which matches the label's 373 women and its Europe and Israel setting, though the label does not say they are the same trial.11 The PubMed record of the 2002 report names no sponsor, no author ties and no limitations.11
Deeper analysis: MEGASET, Devroey and colleagues, Fertility and Sterility, 2012
Devroey and colleagues compared highly purified menotropin with recombinant FSH in 749 women with compulsory single-blastocyst transfer, and report that "Noninferiority of hphMG compared to rFSH was established".13 They add that "Significant differences in pharmacodynamic end points were found between the two gonadotropin preparations".13 The registry entry (NCT00884221) names Ferring Pharmaceuticals as lead sponsor and states that "the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor".14 The registry's adverse event table lists serious adverse events in 5 of 374 women given menotropin and 7 of 375 given recombinant FSH, and other adverse events above its 5 percent threshold in 66 of 374 and 47 of 375.14 The PubMed record names no author ties and no limitations.13
Doses reported in studies and on labels
The app lists a typical dose of 75 to 150 IU. The table gives the doses the label and studies report, each for the people and schedule shown, in the units each source uses.
| Source | People | Dose and route | Schedule and length |
|---|---|---|---|
| Menopur label1 | Women having an assisted reproductive technology cycle after a GnRH agonist1 | 225 International Units subcutaneously, adjusted by no more than 150 International Units; a daily ceiling of 450 International Units1 | Daily from cycle day 2 or 3, adjusted after 5 days; the label's limit is 20 days of therapy1 |
| Devroey and colleagues, 2012 (registry)14 | 749 women, antagonist cycle13 | 150 IU daily to start; adjustments of 75 IU; maximum 375 IU daily14 | First 5 days, then adjusted; no more than 20 days14 |
| Mao and colleagues, 20172 | 182 men with CHH2 | hMG 75 U per injection (150 U in some), mean 97 ± 28 U, with hCG 2000 U (mean 2857 ± 253 U); route of hMG not stated2 | Twice weekly; follow-up 28.7 ± 13.0 months2 |
| Shah and colleagues, 20218 | 35 men with CHH8 | hMG 75 to 150 U with hCG escalated to 2000 U three times a week or 5000 U twice a week, or until testosterone reached 3.5 ng/ml8 | Three times a week; 33 ± 12 months8 |
| Liu and colleagues, 20215 | 20 male adolescents aged 12 to 18 with CHH5 | hMG with 75 U FSH and 75 U LH once daily after 1000 to 2000 U hCG intramuscularly; route of hMG not given in the sections cited5 | hCG for 3 months, then daily hMG; treatment divided into 0 to 3 and 3 to 12 months5 |
Side effects reported
In two trials of 434 women having IVF or ICSI, the Menopur label lists these adverse reactions at 2% or more: abdominal pain (6.7%), headache (6.2%), ovarian hyperstimulation syndrome (OHSS, 6.2%), injection site pain and reaction (3.9%), abdominal cramps (3.0%), enlarged abdomen (2.3%) and injection site inflammation (2.3%).1 The warnings name abnormal ovarian enlargement, OHSS, pulmonary and vascular complications, ovarian torsion and multi-fetal gestation, and state that "In rare cases, pulmonary complications and/or thromboembolic reactions have resulted in death".1 The label also states that "The risk of spontaneous abortion (miscarriage) is increased with gonadotropin products. However, causality has not been established", and that Menopur is contraindicated in pregnancy (Pregnancy Category X).1
In the men of Mao and colleagues, gynecomastia occurred in 16 of 182 (8.8%) on hCG/hMG and 1 of 20 (5.0%) on GnRH (P = 0.083), acne in 11 of 182 (6.0%) and 0 of 20 (P = 0.021), and "No hepatorenal impairment was identified"; 7 of 20 on GnRH (35%) had mild to moderate dermatologic allergic reactions.2 Liu and colleagues report acne in two children in the hCG/hMG group within 3 months and hair loss in one, with the hCG dose reduced in each case, and "No abnormal blood biomarkers were observed in either treatment group".5 Ortaç and colleagues report that "No patients developed severe effects during the treatment period".9
Bloodwork and markers
The app lists total testosterone, free testosterone, estradiol (E2), LH and FSH as markers it associates with HMG. In the 182 men of Mao and colleagues, whose hCG dose was adjusted to keep plasma testosterone at 10 to 15 nmol/l, plasma testosterone rose from 0.9 ± 0.5 to 16.2 ± 8.2 nmol/l after 12 months of hCG/hMG (P < 0.001), against a rise to 8.3 ± 4.6 nmol/l in the 20 men on GnRH.2 The Menopur label says that "Human Chorionic Gonadotropin (hCG) is detected in MENOPUR", and Duijkers and colleagues report that LH immunoactivity after hMG "appeared to be a composite of specific LH and HCG activity".1,6 In the MEGASET registry results, listed as endocrine profile in the intention-to-treat set, estradiol (8797 against 7022), FSH (15.7 against 12.6), LH (2.8 against 2.1), testosterone (2.5 against 2.1) and free androgen index (2.8 against 2.5) were higher with menotropin than with recombinant FSH (p < 0.001 each), prolactin (1544 against 1410, p 0.047) and sex hormone binding globulin (111 against 107, p 0.009) were also higher, and progesterone did not differ (p 0.630).14
Regulatory and anti-doping status
Sources in this part
The Menopur label (Ferring) gives "Initial U.S. Approval: 1975" and its indication is in women having assisted reproduction.1 It states that "Safety and effectiveness in pediatric patients have not been established" and that "No drug/drug interaction studies in humans have been conducted for MENOPUR".1
The text of the WADA 2026 Prohibited List does not contain the names menotropin or menopausal gonadotrophin.15 Section S2.2.1, "Testosterone-stimulating peptides in males including, but not limited to", names chorionic gonadotrophin (CG) and luteinizing hormone (LH), and class S2 is prohibited at all times, in and out of competition, with all substances in it non-Specified Substances.15 The class text adds that "other substances with similar chemical structure or similar biological effect(s), are prohibited".15
Storage and handling
Sources in this part
The Menopur label states that the lyophilized powder "may be stored refrigerated or at room temperature (3° to 25° C/37° to 77°F) until dispensed", with the instructions "Protect from light. Use immediately after reconstitution. Discard unused material".1
What is not known
Sources in this part
- 1Ferring Pharmaceuticals Inc, 2018
- 2Mao et al., 2017
- 3Menon, 2003
- 4Zhao et al., 2019
- 5Liu et al., 2021
- 6Duijkers et al., 1995
- 7Dobbs et al., 1994
- 8Shah et al., 2021
- 9Ortac et al., 2020
- 10Huijben et al., 2026
- 11European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone, 2002
- 12Andersen et al., 2006
- 13Devroey et al., 2012
The label's indication, trials and contraindications are all in women, and it carries no male indication.1
A search of PubMed on 16 November 2026 for menotropin or human menopausal gonadotrophin terms with male-related and with pharmacokinetic, bioavailability or half-life terms in the title or summary text returned 4 records, and none of the 4 titles reports a pharmacokinetic study of hMG in men. The label gives no bioavailability percentage, no duration of activity and no half-life for LH or hCG activity.1
Of the male studies in the table, the placebo-controlled randomised trial (Zhao and colleagues) gives no participant number or dose in its record; Mao, Shah, Ortaç and Liu are retrospective (Liu in 41 male adolescents) and Menon is a single case report.4,2,8,9,3,5 Liu and colleagues give as limitations a short observation period without semen analysis and a small sample.5 Huijben and colleagues write that "the majority of included studies were of low methodological quality, with only one study rated as strong".10
The PubMed records of Menon, Shah, Zhao, Andersen, Devroey, Duijkers, Dobbs and the European and Israeli Study Group name no funder or author ties.3,8,4,12,13,6,7,11 The authors of Ortaç, Liu and Huijben state that they have no conflicts of interest, and Liu and colleagues thank Ferring Pharmaceuticals for donating "highly purified menotrophin (MENOPUR)" and report a grant from the Jin Lei Pediatric Endocrinology Growth Research Fund for Young Physicians.9,5,10
Frequently asked questions
What is the half-life of HMG?
The app lists a half-life of about 36 hours for HMG. The Menopur label gives 11 to 13 hours for FSH after repeated doses in healthy women, and Duijkers and colleagues measured 22.20 and 21.33 hours for FSH and 14.80 and 12.11 hours for HCG after one intravenous dose of two hMG preparations in 9 women.1,6
Is HMG banned by WADA?
The text of the WADA 2026 Prohibited List does not contain the names menotropin or menopausal gonadotrophin.15 Section S2.2.1, testosterone-stimulating peptides in males, names chorionic gonadotrophin (CG) and luteinizing hormone (LH) "including, but not limited to", in a class prohibited at all times.15
What is in HMG?
What is HMG approved for?
What are the side effects of HMG?
In the label's IVF trial, OHSS occurred in 7.2% of the 373 women given Menopur, and multiple pregnancy in 35.3% (n=30) of 85 pregnancies.1 In two trials of 434 women having IVF or ICSI, the label's most frequent adverse reactions were abdominal pain (6.7%), headache (6.2%) and OHSS (6.2%).1 In 182 men given hCG with hMG, gynecomastia occurred in 8.8% and acne in 6.0%.2
Does HMG contain hCG?
How does HMG compare with recombinant FSH?
In MEGASET (749 women; its registry entry names Ferring Pharmaceuticals as lead sponsor), ongoing pregnancy after a fresh cycle was 29% with menotropin and 27% with recombinant FSH by intention to treat, and the authors report that noninferiority was established.13,14 In Andersen and colleagues' 731 women the rates were 27% and 22%, and the authors state that "Superiority of HP-hMG over rFSH in ongoing pregnancy rate could not be concluded from this study, but non-inferiority was established".12
Has HMG been studied in men?
Yes, together with hCG: Mao and colleagues report sperm in 140 of 182 men with CHH (76.9%) after hCG with hMG against 14 of 20 (70.0%) on pulsatile GnRH, with a median of 18 months to first sperm against 6 months.2 The Menopur label carries no male indication, and Huijben and colleagues' review of 1583 men reports that most included studies were of poor methodological quality.1,10
How is HMG stored?
The Menopur label states that the powder "may be stored refrigerated or at room temperature (3° to 25° C/37° to 77°F) until dispensed" and is to be used immediately after reconstitution.1
Guides, tools and comparisons
- How to mix HMGA guide that answers a question on this compound.
- Calculator for HMGA calculator set up for this compound.
- Previous in Post-cycle and ancillaries: HCGThe compound before this one in the class.
- Next in Post-cycle and ancillaries: Letrozole (Femara)The compound after this one in the class.
References
- Ferring Pharmaceuticals Inc. MENOPUR (menotropins) for injection, for subcutaneous use: prescribing information, DailyMed label, Rev: 05/2018. DailyMed. DailyMed Menopur label
- Mao JF, Liu ZX, Nie M, et al. Pulsatile gonadotropin-releasing hormone therapy is associated with earlier spermatogenesis compared to combined gonadotropin therapy in patients with congenital hypogonadotropic hypogonadism. Asian J Androl 2017. PMC5676428
- Menon DK. Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin. Fertil Steril 2003. PMID 12801577
- Zhao N, Lu XL, Li JT, et al. Treatment of idiopathic oligozoospermia with combined human chorionic gonadotropin/human menopausal gonadotrophin: a randomised, double-blinded, placebo-controlled clinical study. Andrologia 2019. PMID 30891813
- Liu Y, Ren XY, Peng YG, et al. Efficacy and safety of human chorionic gonadotropin combined with human menopausal gonadotropin and a gonadotropin-releasing hormone pump for male adolescents with congenital hypogonadotropic hypogonadism. Chin Med J 2021. PMC8143779
- Duijkers IJ, Beerens MC, Coelingh Bennink HJ, et al. Pharmacokinetics of two human menopausal gonadotrophin preparations after single intravenous administration during pituitary suppression. Hum Reprod 1995. PMID 7593498
- Dobbs KE, Dumesic DA, Dumesic JA, et al. Differences in serum follicle-stimulating hormone uptake after intramuscular and subcutaneous human menopausal gonadotropin injection. Fertil Steril 1994. PMID 7926145
- Shah R, Patil V, Sarathi V, et al. Prior testosterone replacement therapy may impact spermatogenic response to combined gonadotropin therapy in severe congenital hypogonadotropic hypogonadism. Pituitary 2021. PMID 33226541
- Ortac M, Hidir M, Cilesiz NC, et al. Efficacy of follitropin-alpha versus human menopausal gonadotropin for male patients with congenital hypogonadotropic hypogonadism. Turk J Urol 2020. PMID 31905120
- Huijben M, Prinsen A, de Kort L, et al. Boosting male fertility: the impact of gonadotropin therapy on hypogonadotropic hypogonadism - a systematic review and meta-analysis. Andrology 2026. PMC13592061
- European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone. Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial. Fertil Steril 2002. PMID 12215327
- Andersen AN, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod 2006. PMID 16873892
- Devroey P, Pellicer A, Nyboe Andersen A, et al. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertil Steril 2012. PMID 22244781
- Ferring Pharmaceuticals. MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer (MEGASET). ClinicalTrials.gov NCT00884221, record accessed 16 November 2026. NCT00884221
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA Prohibited List 2026